Samsung Bioepis and Teva have entered into a global licensing, development and commercialization agreement for up to six potential biosimilars.
Two candidates have been confirmed: SB41, with Fasenra as the reference product, and SB44, with Ilaris as the reference product.
Samsung Bioepis will be responsible for development, regulatory registration and manufacturing, while Teva will handle commercialization, including in the US, Europe and Canada.
